{"brief_title": "Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)", "brief_summary": "The aim of the study is to compare the effects of oral roflumilast with placebo on lung function in patients with asthma.", "condition": "Asthma", "intervention_type": "Drug", "intervention_name": "Roflumilast", "criteria": "Main Inclusion Criteria: - Persistent bronchial asthma - No change in asthma treatment within 4 weeks prior to visit 1 - Non-smoker or ex-smoker (for 12 months or longer) Main Exclusion Criteria: - Poorly controlled asthma or seasonal asthma - History of lower airway infection four weeks prior to visit 1 - Chronic obstructive pulmonary disease (COPD) and/or other relevant lung disease - Patients using > 8-puffs/day-short-acting bronchodilator (beta-agonists) (more than 3 days per week on average) prior to visit 1 - Clinically relevant abnormal laboratory values suggesting an undiagnosed disease, severe renal insufficiency, active hepatitis or an HIV infection - Diagnosis, treatment or remission of any cancer (other than basal cell carcinoma) within two years prior to visit 1 - Patients with chronic heart failure - Suspected hypersensitivity and/or contraindication to roflumilast or albuterol/salbutamol - Female patients of childbearing potential not using adequate means of birth control or pregnant or breast-feeding females - Patients who have received any investigational medication or device in the month prior to visit 1 or who plan to use another investigational medication during the study", "gender": "All", "minimum_age": "18 Years", "maximum_age": "70 Years", "healthy_volunteers": "No", "id": "NCT00073177.xml"}